VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a report released on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark reissued a "hold" rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Stock Down 4.7 %

VolitionRx stock traded down $0.03 during mid-day trading on Friday, hitting $0.70. The company's stock had a trading volume of 91,445 shares, compared to its average volume of 162,128. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The stock's fifty day moving average price is $0.68 and its two-hundred day moving average price is $0.69. The stock has a market capitalization of $57.66 million, a P/E ratio of -1.51 and a beta of 1.09.

VolitionRx (NYSE:VNRX - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. Equities analysts expect that VolitionRx will post -0.31 earnings per share for the current year.

Insider Buying and Selling at VolitionRx

In related news, Director Guy Archibald Innes purchased 150,000 shares of VolitionRx stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $0.67 per share, with a total value of $100,500.00. Following the completion of the transaction, the director now directly owns 406,683 shares of the company's stock, valued at $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.80% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.